Please login to the form below
MDR
This page shows the latest MDR news and features for those working in and with pharma, biotech and healthcare.
FDA green lights study of phage-based drug for resistant infections
One company working in this area – Adaptive Phage Therapeutics – has just won FDA approval to start human testing of personalised bacteriophage therapeutics for serious MDR infections. ... strain. Arms of the study will also focus on specific bacteria
Latest news
-
Merck preps regulatory filings for much-needed antibiotic combo
An independent UK review estimated that by 2050 MDR infections could claim 10 million lives a year and result in a cumulative loss from global output of $100trn. ... rates of multidrug resistant (MDR) strains, the need for new treatment options is
-
Pharma must do more on antibiotic resistance, Davos meeting hears
In particular, more needs to be done to bring forward new drugs for multidrug resistant (MDR) pathogens or ‘superbugs’ - there are currently 28 novel drugs for high-priority pathogens in phase
-
Pfizer launches antibiotic resistance surveillance website
Meanwhile, Pfizer’s new antibiotic for multidrug resistant (MDR) infections, Zavicefta, was launched in its first European markets earlier this year after the pharma firm paid its developer AstraZeneca $1.58bn
-
Pfizer launches new antibiotic Zavicefta in UK and Germany
MDR infections are an increasing global threat," said Matteo Bassetti, chief of the infectious diseases Clinic at University of Udine in Italy. ... The availability of Zavicefta is a major step forward for physicians faced with the challenge of treating
-
AZ slims down again with sale of antibiotics to Pfizer
ATM-AVI is in trials for life-threatening Gram-negative bacterial infections caused by multi-drug resistant (MDR) strains, while CXL has activity against MDR Gram-positive and Gram-negative pathogens.
More from news
Approximately 4 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Medical device regulation - a risk-based approach to compliance
Simply put, complying with MDR is another stressor for medtechs at an already challenging time, potentially affecting both top- and bottom-line growth. ... It's difficult to estimate just how great the costs associated with MDR implementation will
More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Hydroxychloroquine fails trial as preventative measure against COVID-19
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Regeneron says antibody for COVID-19 could be ready this year
- AstraZeneca forges agreements for equal access to COVID-19 vaccine
- Hydroxychloroquine safety study pulled on data integrity concern
- UCB buys epilepsy firm Engage Tx in $270m deal
- With knowledge and position comes responsibility
- How healthcare comms needs to adapt
- Hydroxychloroquine fails trial as preventative measure against COVID-19
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- AI and genomics: a revolution in drug discovery and development
- ...
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Quick links
Infographics
